Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients

Inclusion criteria * Age between 30 and 50 years * Both genders * BMI between 30 and 40 * Stable body weigh defined by over 5 per cent variability during the previous 3 months * Fasting serum glucose less than 126 mg per dl * Blood pressure over 140 and 90 mmHg * Women ensuring contraceptive precautions. * Communication and understanding capability. * Informed consent awarding. Exclusion criteria * Women were excluded if they were pregnant or lactating potential while no taking adequate contraceptive precautions * Any smoking during the preceding 6 months * No physical activity, defined by less than 15 minutes per day of walking * Excessive physical activity equivalent to running over 60 minutes per day * Known hypersensitivity to sibutramine or metformin * Low commitment to follow the protocol statements * Any investigational medication during the preceding 6 months * Any drug or substance mayor toxicity exposure during the preceding 3 months * Alcohol or any drug abuse during the previous 3 months * Current medication of oral corticosteroids, anticoagulants, sympathomimetics, sympatholytics, lipid lowering drugs, any medication for type 2 diabetes, and any sibutramine interaction drug * Current or previous evidence of ischemic heart disease, cardiac arrhythmia, cerebrovascular disease, chronic hepatic disease, two fold persistent elevation of ALT, AST or FA * Carrying a pacemaker or any permanent bioelectronic component that could interfere with bioimpedance process * Renal failure defined by serum creatinine equal or ever 1.2 mg per dL * Not controlled thyroid disease defined by altered serum T3, T4 and TSH during the previous 3 months * Hypertension * Type 2 diabetes * Anti-depressants, or any psychiatric disturbance treatment